fifaxa

CIBC Personal Wealth Group LLC diminished its holdings in Edwards Lifesciences Co. (NYSE:EW – Get Ranking ) by 3.0% within the third quarter, in response to its most up-to-date Kind 13F submitting with the Securities and Trade Fee. The agency owned 1,916,447 shares of the medical analysis firm’s inventory after promoting 58,671 shares through the quarter. CIBC Personal Wealth Group LLC owned about 0.31% of Edwards Lifesciences value $158,357,000 as of its most up-to-date submitting with the Securities and Trade Fee.

China threatens US protection and financial safety (From Investing Traits)

Quite a few different institutional buyers and hedge funds have additionally lately added to or diminished their stakes within the enterprise. Covington Capital Administration raised its stake in Edwards Lifesciences by 2.6% within the third quarter. Covington Capital Administration now owns 147,307 shares of the medical analysis firm’s inventory value $12,172,000 after buying an extra 3,745 shares through the interval. CreativeOne Wealth LLC lifted its place in Edwards Lifesciences by 2.4% through the third quarter. CreativeOne Wealth LLC now owns 11,972 shares of the medical analysis firm’s inventory valued at $989,000 after shopping for an extra 282 shares through the interval. Meiji Yasuda Life Insurance coverage Co elevated its place in Edwards Lifesciences by 6.6% through the third quarter. Meiji Yasuda Life Insurance coverage Co now owns 11,934 shares of the medical analysis firm’s inventory valued at $986,000 after shopping for an extra 738 shares through the interval. United Companies Vehicle Affiliation raised its place in Edwards Lifesciences by 6.5% through the third quarter. United Companies Vehicle Affiliation now owns 24,346 shares of the medical analysis firm’s inventory valued at $2,011,000 after shopping for an extra 1,487 shares through the interval. Lastly, Verus Capital Companions LLC lifted its place in Edwards Lifesciences by 220.0% through the third quarter. Verus Capital Companions LLC now owns 4,330 shares of the medical analysis firm’s inventory valued at $358,000 after shopping for an extra 2,977 shares through the interval. Hedge funds and different institutional buyers personal 80.35% of the corporate’s inventory.

Wall Avenue analysts predict progress

A number of equities analysts have commented on the corporate. Canaccord Genuity Group boosted their worth goal on Edwards Lifesciences from $68.00 to $76.00 and gave the corporate a “maintain” score in a analysis report on Wednesday, February 1st. Morgan Stanley boosted their worth goal on Edwards Lifesciences from $92.00 to $95.00 and gave the corporate an “obese” score in a analysis report on Friday, January sixth. Canaccord Genuity Group lower their worth goal on Edwards Lifesciences from $78.00 to $73.00 and set a “maintain” score for the corporate in a analysis report on Monday, December twelfth. Sanford C. Bernstein downgraded Edwards Lifesciences from an “outperform” score to an “underperform” score and diminished their worth goal for the inventory from $95.00 to $66.00 in a analysis report on Tuesday, January thirty first. Lastly, Citigroup diminished their worth goal on Edwards Lifesciences from $99.00 to $92.00 and set a “purchase” score for the corporate in a analysis report on Monday, December twelfth. One analysis analyst has rated the inventory with a promote score, ten have issued a maintain score and eight have given a purchase score to the corporate’s inventory. Edwards Lifesciences has a median score of “Maintain” and a median goal worth of $88.95, based mostly on knowledge from MarketBeat.

Edwards Lifesciences Inventory Efficiency

Shares of EW inventory traded up $0.75 throughout buying and selling hours on Monday, reaching $75.09. 1,670,977 shares of the corporate traded palms, in comparison with its common quantity of three,425,965. Edwards Lifesciences Co. it has a 12 month low of $67.13 and a 12 month excessive of $131.10. The corporate has a debt-to-equity ratio of 0.10, a present ratio of three.03, and a fast ratio of two.17. The corporate has a market cap of $45.68 billion, a P/E ratio of 30.47, a P/E/G ratio of 4.33 and a beta of 1.01. The corporate has a 50-day transferring common of $77.96 and a 200-day transferring common of $79.75.

Edwards Lifesciences (NYSE:EW – Get Ranking ) final posted its quarterly earnings outcomes on Tuesday, January thirty first. The medical analysis firm reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.03. Edwards Lifesciences had a return on fairness of 26.05% and a web margin of 28.27%. The corporate had income of $1.35 billion for the quarter, in comparison with analysts’ expectations of $1.33 billion. Throughout the identical interval final 12 months, the corporate earned $0.51 EPS. The corporate’s income was up 1.5% in comparison with the identical quarter final 12 months. As a bunch, sell-side analysts predict that Edwards Lifesciences Co. will put up earnings of two.52 per share for the present fiscal 12 months.

Insider Shopping for and Promoting

In different information, VP Jean-Luc M. Lemercier bought 6,640 shares of the corporate’s inventory in a transaction that occurred on Wednesday, March eighth. The inventory was bought at a median worth of $76.96, for a complete transaction of $511,014.40. Following the sale, the vp now straight owns 168,875 shares within the firm, valued at roughly $12,996,620. The sale was disclosed in a authorized submitting with the Securities and Trade Fee, which might be accessed by way of this hyperlink. In different information, VP Jean-Luc M. Lemercier bought 6,640 shares of the corporate’s inventory in a transaction that occurred on Wednesday, March eighth. The inventory was bought at a median worth of $76.96, for a complete transaction of $511,014.40. Following the sale, the vp now straight owns 168,875 shares within the firm, valued at roughly $12,996,620. The sale was disclosed in a authorized submitting with the Securities and Trade Fee, which might be accessed by way of this hyperlink. Additionally, Vice President Donald E. Bobo, Jr. bought 6,725 shares of the corporate’s inventory in a transaction that occurred on Monday, February sixth. The inventory was bought at a median worth of $80.75, for a complete worth of $543,043.75. Following the sale, the vp now straight owns 62,561 shares within the firm, valued at $5,051,800.75. Disclosure for this sale might be discovered right here. During the last three months, insiders have bought 101,386 shares of firm inventory valued at $7,834,077. Company insiders personal 1.29% of the corporate’s inventory.

Edwards Lifesciences Firm Profile

(Get Ranking)

Edwards Lifesciences Corp. engages in patient-centered medical improvements for cardiac and significant care monitoring. Its merchandise are categorized into 4 principal areas: Transcatheter Aortic Valve Substitute, Transcatheter Mitral and Tricuspid Therapies, Structural Coronary heart Surgical procedure and Essential Care.

Additional studying

This instantaneous information alert is powered by narrative science know-how and monetary knowledge from MarketBeat to supply readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial group previous to publication. Ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you think about Edwards Lifesciences, you may need to hear this.

MarketBeat tracks Wall Avenue’s high and finest performing analysis analysts each day and the shares they advocate to their purchasers. MarketBeat recognized the 5 shares high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Edwards Lifesciences wasn’t on the record.

Whereas Edwards Lifesciences at present has a “Maintain” score amongst analysts, high analysts imagine these 5 shares are higher buys.

See the 5 shares right here